<DOC>
	<DOCNO>NCT01408342</DOCNO>
	<brief_summary>The purpose study evaluate efficacy combination alemtuzumab rituximab first line therapy aplastic anemia .</brief_summary>
	<brief_title>Alemtuzumab Rituximab Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients aplastic anemia diagnosis Patients prior treatment monoclonal antibody and/or antithymocyte globulin . Patients diagnosis history HIV/AIDS , Hepatitis B , Hepatitis C , Cytomegalovirus . Patients agree sign Letter Informed Consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Aplastic anemia</keyword>
	<keyword>cyclosporine</keyword>
</DOC>